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Abstract
Sprouty proteins (Sproutys) inhibit receptor tyrosine kinase signaling and control various aspects of branching
morphogenesis. In this study, we examined the physiological function of Sproutys in angiogenesis, using gene targeting
and short-hairpin RNA (shRNA) knockdown strategies. Sprouty2 and Sprouty4 double knockout (KO) (DKO) mice were
embryonic-lethal around E12.5 due to cardiovascular defects. The number of peripheral blood vessels, but not that of
lymphatic vessels, was increased in Sprouty4 KO mice compared with wild-type (WT) mice. Sprouty4 KO mice were more
resistant to hind limb ischemia and soft tissue ischemia than WT mice were, because Sprouty4 deficiency causes accelerated
neovascularization. Moreover, suppression of Sprouty2 and Sprouty4 expression in vivo by shRNA targeting accelerated
angiogenesis and has a therapeutic effect in a mouse model of hind limb ischemia. These data suggest that Sproutys are
physiologically important negative regulators of angiogenesis in vivo and novel therapeutic targets for treating peripheral
ischemic diseases.
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Introduction
Growth factor-induced signaling by receptor tyrosine kinases
(RTKs) plays several essential roles in development and patho-
genesis; accordingly, it is tightly controlled by a number of
regulatory proteins [1–3]. When a ligand binds to an RTK and
recruits a Grb2-Sos to the inner surface of a membrane, the Sos
protein binds to Ras, causing GDP/GTP exchange and thus
activating Ras. Activated Ras recruits Raf to the plasma
membrane and activates the Raf/MEK/extracellular signal-
regulated kinase (ERK) pathway. Some growth factors, such as
vascular endothelial growth factor (VEGF)-A, also activate the
Raf/MEK/ERK pathway through the RTK/phospholipase C
(PLC)-c/protein kinase C (PKC) pathway, which is a Ras-
independent pathway [4].
Sprouty (Spry) has been genetically identified as an antagonist of
fibroblast growth factor (FGF) receptor in tracheal development in
Drosophila, and is a proven negative regulator of the Ras/Raf/
ERK pathway [5,6]. Four mammalian genes with sequence
similarity to Drosophila Sprouty (Sprouty1–4) have been identified
[1,2]. In addition, we have identified three Sprouty-related
proteins known as Spred1–3 (Spreds), in which the C-terminal
cysteine-rich domain found in Sprouty proteins (Sproutys) is
conserved [7,8]. Since loss-of-function mutations of the SPRED1
gene have been found in human neuro-cardio-facial-cutaneous
(NCFC) syndromes [9], and since these syndromes are caused by
dysregulation of the Ras-ERK pathway, we conclude that
SPRED1 is a negative regulator of RTK-mediated Ras/ERK
activation.
In the development of the cardiovascular system of Drosophila,a s
in the tracheal system, the formation of new blood vessels from
preexisting ones (angiogenesis) involves the sprouting of endothe-
lial cells out of an epithelial layer and the branching of tubular
structures [10]. In the adult, angiogenesis only takes place during
the female reproductive cycle, during wound healing, and in
pathological situations, including tumor growth, diabetic retinop-
athy, arthritis, atherosclerosis, and psoriasis [10,11]. Angiogenesis
is tightly regulated by a balance between inducing and inhibitory
signals [12]. Growth factors, such as VEGF-A, basic FGF (bFGF),
and angiopoietins, positively regulate angiogenesis by binding to
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ation, migration, differentiation, and survival [12,13]. In addition,
sphingosine-1-phosphate (S1P), which activates GPCRs, has also
been implicated in angiogenesis [14]. In contrast, proteins that
negatively regulate angiogenesis by specifically blocking RTK
signaling are less well characterized.
Previous studies have demonstrated that overexpression of
Sproutys inhibits VEGF-A- and bFGF-induced endothelial cell
proliferation and differentiation in vitro as well as branching and
sprouting of small vessels in vivo [15,16]. Moreover, Sprouty4
suppresses VEGF-A/VEGF receptor (VEGFR)-2 signaling in vitro
[17–19]. We also know that Spreds, in contrast, inhibit VEGF-C
signaling, which is important in lymphangiogenesis, and that
Spred1/Spred2 double knockout (KO) (DKO) mice show abnormal
lymphatic development [18]. Yet the physiological role of Sproutys
in angiogenesis and lymphangiogenesis remains to be elucidated.
In this study we investigated the physiological function of
Sproutys in angiogenesis by performing knockout and knockdown
analyses of Sproutys. We showed that Sproutys are negative
regulators for angiogenesis rather than lymphangiogenesis in vivo.
Moreover, Sprouty4 KO mice were more resistant to hind limb
ischemia and soft tissue ischemia than wild-type (WT) mice were,
and in vivo shRNA targeting Sprouty2 and Sprouty4 accelerated
angiogenesis in a mouse model of hind limb ischemia. These data
suggest that Sprouty2 and Sprouty4 are important negative
regulators of angiogenesis in vivo that could be new therapeutic
targets for ischemic diseases.
Results
Increased developmental angiogenesis in Sprouty-
deficient mice
Overexpression studies suggest that Sprouty2 and Sprouty4
possess similar negative effects on RTK-mediated ERK activation
[20]. To define the overlapping functions of Sprouty2 and
Sprouty4, we generated Sprouty2/Sprouty4 DKO mice. Sprouty2/
Sprouty4 DKO mice were embryonic-lethal by embryonic day 12.5
and showed very severe defects in craniofacial and limb
morphogenesis [21]. They also showed very severe subcutaneous
hemorrhage, edema (Fig. 1A–D), and multiple hepatic hemangi-
omas (Fig. 1E,F), which suggested that they had cardiovascular
defects as well. We next investigated the expression pattern of
Sprouty2 and Sprouty4 in endothelial cells during embryonic
development, and found that Sprouty2 and Sprouty4 were more
highly expressed in blood endothelial cells (BECs) than in
lymphatic endothelial cells (LECs) (Fig. 1G).
This discovery led us to examine vascularization in adult
Sprouty4 single KO mice in detail, although Sprouty4 single KO
Figure 1. Characterization of Sprouty2/Sprouty4 DKO mice. (A, B) Gross appearance of wild-type (WT) (A) and Sprouty2/Sprouty4 DKO (B)
embryos at embryonic day 12.5. The arrow and arrowheads indicate hemorrhage and edema, respectively. (C, D) Hematoxylin-eosin (H&E) staining of
sections of WT (C) and Sprouty2/Sprouty4 DKO (D) skin. (E, F) H&E staining and immunohistochemical staining with von Willebrand factor (vWF) of
sections of hepatic hemangiomas in Sprouty2/Sprouty4 DKO liver. vWF was used as a blood vessel marker. (G) Expression of Sproutys in endothelial
cells. About 5.0610
4 BECs and LECs were FACS-sorted at embryonic day 14.5, and were used for RT-PCR analysis. GAPDH served as a loading control.
Good separation of BECs and LECs was confirmed by BEC markers (Nrp1, CD44) and LEC markers (LYVE1, Prox1). Scale bars (C–F): 100 mm.
doi:10.1371/journal.pone.0005467.g001
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KO mice exhibited more vascular networks of blood vessels in the
ear than WT mice did (Fig. 2A,B). Similarly, more vascular
networks of blood vessels in the ear were observed in Sprouty2
single KO mice than in WT mice (data not shown). The numbers
of blood vessels in the skin were also increased in Sprouty4 KO mice
(Fig. 2C,D). Lymphatic vessel networks, on the other hand, were
present at the same frequency in these Sprouty4 KO mice as in WT
mice (Fig. 2A–D). Retinal vasculature is a good model system for
the study of general blood vessel development [22]. Vascular
development in the early embryo is difficult to observe, but the
murine retinal vascular system develops after birth and is therefore
easier to examine. We compared flat-mounted retinas from WT
and Sprouty4 KO mice at postnatal day (PD) 3 after injecting
FITC-dextran (Fig. 2E). As the image clearly shows, retinal
angiogenesis was enhanced in Sprouty4 KO mice compared to WT
mice.
These data suggest that, in contrast to Spred1 and Spred2,
which are important negative regulators of developmental
lymphangiogenesis rather than developmental angiogenesis, as
previously reported [18], Sprouty2 and Sprouty4 are important
negative regulators of developmental angiogenesis rather than
developmental lymphangiogenesis.
Sprouty4 KO mice are more resistant to ischemia
Next, we sought to investigate the effect of Sprouty4 deficiency in
the ischemia-induced angiogenesis model, an adult neovascular-
ization assay which is useful for quantifying neovascularization in
Sprouty4 KO mice. We used mouse models of hind limb ischemia
[23] and soft tissue ischemia [24]. We used Sprouty4 KO mice,
since Sprouty4 KO mice can survive much longer than Sprouty2 KO
mice [21,25].
The former model revealed that Sprouty4 KO mice were more
resistant to hind limb ischemia than WT mice were (Fig. 3A).
Sprouty4 KO mice showed a significantly elevated recovery of limb
perfusion after induction of hind limb ischemia as compared with
WT mice, and the ischemic/non-ischemic leg perfusion ratio was
much more favorable in Sprouty4 KO mice than in WT mice
(P,0.001) (Fig. 3B,C). Additionally, angiogenesis in the ischemic
hind limb was significantly increased in Sprouty4 KO mice
compared with WT mice (Fig. 3D).
The latter model was induced by creating lateral skin incisions
on the dorsal surfaces of mice. The overlying skin was
undermined, and a silicone sheet was inserted into each mouse
to separate the skin from the underlying tissue bed. As a result, the
most central portion of skin underwent the most severe ischemic
insult, which, in WT mice, ultimately led to the absence of flow
and necrosis in the central portion of the skin (Fig. 4A). In Sprouty4
KO mice, however, angiogenesis in the dorsal skin was
significantly increased compared to that in WT mice (Fig. 4B).
As a result, Sprouty4 KO mice were more resistant to soft tissue
ischemia than WT mice were, and gross evidence of necrosis in the
dorsal skin was more evident in WT mice than in Sprouty4 KO
mice (100% and 16.7% in WT mice and Sprouty4 KO mice,
respectively, n=6) (Fig. 4A).
These data show that Sprouty4 KO mice exhibit enhanced
neovascularization in ischemia-induced models.
Increased ischemia-induced neovascularization by in vivo
shRNA targeting Sproutys
The increased vessel density in the skin and muscles of
untreated Sprouty4 KO mice (Fig. 2C,D, Fig. 3D) provides them
with elevated blood-vessel area in these regions, which is partially
responsible for their increased resistance to ischemia.
To investigate in vivo the efficiency of down-regulating
Sproutys as therapy for peripheral ischemic diseases, we
administered ischemia treatment to the hind limbs of
C57BL/6J mice, then injected shRNA targeting Sprouty2 and
Sprouty4. We suppressed both Sprouty2 and Sprouty4 simulta-
neously, because both of the mRNAs increased during hind
limb ischemia (Fig. 5A), because the phenotype of Sprouty2/
Sprouty4 DKO mice demonstrated a redundant role of Sprouty2
and Sprouty4 in angiogenesis (Fig. 1), and because we have not
found any functional differences between Sprouty2 and
Sprouty4 in vitro [20]. The shRNA plasmid targeting Sprouty2
and Sprouty4 efficiently suppressed the expression levels of
endogenous Sprouty2 and Sprouty4, respectively, in both real-
time PCR (Fig. 5B,C) and Western blot (Fig. 5D,E) analysis.
The shRNA plasmids targeting both Sprouty2 and Sprouty4
enhanced VEGF-A-induced ERK and Akt activation in vitro in
mouse embryonic fibroblasts (MEFs), which stably expressed
VEGFR-2 (Fig. 5F). We used MEFs because it has been very
difficult to introduce shRNA into primary murine endothelial
cells in vitro. Although we confirmed that shRNA against
Sprouty2 or Sprouty4 alone enhanced VEGF-A-induced ERK
and Akt activation (data not shown), we observed much
stronger effect by the combination of Sprouty2 and Sprouty4
shRNAs. Thus we decide to use combination of both Sprouty2
and Sprouty4 shRNAs for further experiments.
First, we showed that injection of shRNA plasmids targeting
Sprouty2 and Sprouty4 significantly enhanced corneal neovascular-
ization induced by VEGF-A, compared to control shRNA
plasmids in a corneal micropocket assay (Fig. 6A–C). These data
indicate that Sprouty2 and Sprouty4 shRNA plasmids can efficiently
suppress the expression levels of Sprouty2 and Sprouty4 and block
the effect of endogenous Sprouty2 and Sprouty4 in vitro and in vivo.
Next, we investigated whether Sprouty2 and Sprouty4 shRNA
plasmids were effective in a mouse model of hind limb ischemia.
Upon injection to the ischemic adductor muscle, Sprouty2 and
Sprouty4 shRNA plasmids reduced Sprouty2 and Sprouty4 expression
in vivo (Fig. 5A). Sprouty2 and Sprouty4 shRNA plasmids induced a
significantly elevated recovery of limb perfusion after induction of
hind limb ischemia as compared with control shRNA plasmids,
and markedly improved the ischemic/non-ischemic leg perfusion
ratio (P,0.05) (Fig. 7A,B). shRNA plasmids targeting Sprouty2 and
Sprouty4 also increased capillary density compared with control
shRNA plasmids (Fig. 7C). Our data clearly demonstrate that
Sprouty2 and Sprouty4 negatively regulate angiogenesis in vivo and
would make good therapeutic targets for peripheral ischemic
diseases.
Discussion
In this study, we investigated the physiological function of
Sproutys in angiogenesis by performing a knockout and knock-
down analysis of Sproutys. In contrast to Spred1 and Spred2, which
regulate developmental lymphangiogenesis, Sprouty2 and Spro-
uty4 are important negative regulators of developmental angio-
genesis in vivo. We found that the amounts of blood vessels in
Sprouty4 KO mice are increased in all tissues we investigated. So
we think that all peripheral blood vessels are increased in Sprouty4
KO mice. Sprouty4 deficiency enhanced ischemia-induced angio-
genesis in mouse models of hind limb ischemia and soft tissue
ischemia. Moreover, the suppression of Sprouty2 and Sprouty4
expression in vivo by shRNA targeting had a therapeutic effect in
our model of hind limb ischemia, indicating that Sproutys should
be novel therapeutic targets for treating peripheral ischemic
diseases.
Sproutys Inhibit Angiogenesis
PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5467Figure 2. Blood and lymphatic vessels of Sprouty4 single KO mice. (A) Blood vessels (green) and lymphatic vessels (red) in the ears of WT and
Sprouty4 KO mice (8 weeks old) were analyzed by whole-mount immunohistochemical staining with anti-PECAM-1/CD31Ab and anti-LYVE-1 Ab,
respectively. (B) CD31-positive vessel area or LYVE1-positive area was quantified. Data shown are means6SEM. *: P,0.05. (C) Blood vessels (green)
and lymphatic vessels (red) in the dorsal skin of WT and Sprouty4 KO mice (8 weeks old) were analyzed by immunohistochemical staining with anti-
PECAM-1/CD31Ab and anti-LYVE-1 Ab, respectively. Nuclei were stained with Hoechst 33342 dye (Blue). (D) CD31-positive vessel area or LYVE1-
positive area was quantified. Data shown are means6SEM. *: P,0.05. (E) FITC-dextran-perfused flat-mounted retinal samples of WT and Sprouty4 KO
mice at postnatal day 3. Scale bars (A, C): 100 mm.
doi:10.1371/journal.pone.0005467.g002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5467The roles of Sprouty and Spred proteins during gastrulation in
Xenopus tropicalis have been compared elsewhere [26]. Spred
proteins preferentially inhibit the Ras/ERK cascade that directs
mesoderm formation, whereas Sprouty proteins block the Ca
2+
and PKCd signals required for morphogenetic movements during
gastrulation. Thus, the expression of Sprouty and Spred genes at
specific times during gastrulation might redirect FGF signals
toward mesoderm formation or morphogenesis, respectively [26].
In mammalian development, Sproutys are expressed mainly in
blood endothelial cells, while Spreds are expressed mainly in
lymphatic endothelial cells (Fig. 1G and Ref. [18]). In overex-
pression experiments, while Sproutys can inhibit VEGF-A
signaling but not VEGF-C signaling, Spreds can suppress both
types (Taniguchi K., unpublished data and Ref. [18]). Indeed,
microRNA-126 deletion suppresses VEGF-A-induced ERK acti-
vation in endothelial cells and angiogenesis through the increase of
Figure 3. Sprouty4 KO mice are more resistant in a hind-limb ischemia model. (A) Representative photos of ischemic limbs, indicated by
arrows. (B) Representative laser Doppler images for each group are depicted. Arrowheads indicate ischemic limbs. The interval of low perfusion is
displayed as dark blue; the highest perfusion interval is displayed as red. (C) Recovery of limb perfusion in WT (n=10) and Sprouty4 KO (n=7) mice
after hind limb ischemia as assessed by laser Doppler blood flow analysis on day 14. Data shown are means6SD. *: P,0.001. (D) Blood vessels (green)
in the non-ischemic or ischemic adductor muscles of male WT and Sprouty4 KO mice (8–10 weeks old) were analyzed by immunohistochemical
staining with anti-PECAM-1/CD31Ab. Nuclei were stained with Hoechst 33342 dye (blue). The CD31-positive vessel area was quantified. Data shown
are means6SEM. *: P,0.05. Scale bars: (D) 100 mm.
doi:10.1371/journal.pone.0005467.g003
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specific to VEGF-A signaling than to VEGF-C signaling, while the
effect of Spred deletion is more specific to VEGF-C signaling than
to VEGF-A signaling (Taniguchi K., unpublished data and Ref.
[18]). In fact, Sprouty2 and Sprouty4 single-deficient mice showed
defects of blood vessels rather than lymphatic vessels, while Spred1/
Spred2 DKO mice showed abnormal lymphatic vessel development
and nearly normal blood vessel development (Fig. 2 and Ref. [18]).
In addition to this difference in expression, these results suggest
that Sproutys and Spreds might have different functions in
endothelial cells. VEGF-A/VEGFR-2 signaling is Ras-indepen-
dent and PLC-c/PKC-dependent, while VEGF-C/VEGFR-3
signaling is Ras-dependent and PKC-independent (Taniguchi
K., unpublished data and Ref. [4]). Therefore, drawing an analogy
from the different functions of Sproutys and Spreds in Xenopus
tropicalis, we propose that Sproutys inhibit PLC-c/PKC-dependent
VEGF-A signaling and angiogenesis, while Spreds inhibit Ras-
dependent VEGF-C signaling and lymphangiogenesis.
Although, in ischemia-induced angiogenesis, VEGF-A is
thought to be the primary angiogenesis-stimulating factor [30],
angiogenesis is the more complex process, as it is triggered not
only by VEGF-A but also by bFGF, S1P, angiopoietins, and others
[12–14]. In fact, it is reported that bFGF gene therapy is effective
to treat critically ischemic limb [31]. It is already known that
Sproutys can inhibit various RTK signals [1,2]. We have also
shown that loss of Sprouty expression results in hyperactivation of
VEGF-A and bFGF signaling as well as S1P and LPA signaling
(Fig. 5F, Taniguchi K., unpublished data and Ref. [19] and [21]).
It is reported that in vivo shRNA targeting SHP-1 also accelerated
angiogenesis in a rat model of hind limb ischemia [32]. While
SHP-1 inhibits only RTK signals, Sproutys suppress both RTK
and GPCR signals. Thus the suppression of Sproutys could be
beneficial.
Inhibition of negative feed-back loops leading to profound and
long term activation of signals often lead to a dysregulation of
neovascularisation since the overshooting response is inducing
immature vessels. However, excessive sprouting in response to
inhibition of Sproutys results in the formation of mature vessels.
Angiogenesis is a complex process that includes the recruitment
and proliferation of various cells, such as endothelial cells, mural
cells [smooth muscle cells (SMC) and pericytes], endothelial
progenitor cells (EPCs) and others. It is reported that Sprouty-family
genes are expressed in both endothelial cells and smooth muscle
cells [33], and we have confirmed that Sprouty/Spred family genes
are also expressed in bone marrow (Taniguchi K., unpublished
data). It is possible that Sproutys function not only in endothelial
cells, but also in mural cells, EPCs or myeloid cells, and that
enhanced angiogenesis of mature vessels in Sprouty4 KO mice and
Figure 4. Sprouty4 KO mice are also more resistant in a soft tissue ischemia model. (A) Representative photos of ischemic dorsal skin of
male WT and Sprouty4 KO mice (8–10 weeks old). Arrows indicate necrotic skin. (B) Left: Blood vessels (green) in the ischemic dorsal skin of male WT
and Sprouty4 KO mice were analyzed by immunohistochemical staining with anti-PECAM-1/CD31Ab. Nuclei were stained with Hoechst 33342 dye
(blue). Right: The CD31-positive vessel area was quantified. Data shown are means6SEM. *: P,0.05. Scale bars (B): 100 mm.
doi:10.1371/journal.pone.0005467.g004
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PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5467the results of our experiments with in vivo shRNA targeting Sproutys
are partially dependent on the enhanced function or the increased
number of mural cells, EPCs or myeloid cells. Moreover, it is
possible that Sproutys are also associated with angiopoietins
signals, which are important for the maturation of blood vessels.
Further study is necessary to investigate these possibilities.
Sprouty4 KO mice were more resistant to ischemia than WT mice
were in mouse models of ischemia (Fig. 3, Fig. 4), and neovascular-
ization induced by a tumor transplantation model was also
accelerated by Sprouty4 deficiency (Taniguchi K., unpublished data).
Moreover, in vivo shRNA targeting Sprouty2 and Sprouty4 accelerated
angiogenesis in a mouse model of hind limb ischemia (Fig. 7). In this
study,muscletissueinjectedwiththeSproutysshRNAvectorsexhibited
asignificantdecreaseinSproutystranscripts(Fig.5A).Thisknockdown
efficiency may be due to the fact, in skeletal muscle, the efficiency of
intramuscular gene transfer has been shown to be augmented from
five- to seven-fold when the injected muscle is ischemic [34]. The
present study is the first to uncover these significant implications for
gene therapy using the Sprouty2 and Sprouty4 shRNA vectors for the
treatment of peripheral ischemic diseases. The fact that Sproutys
exhibit such broad suppression activity, inhibiting a wide variety of
angiogenic factors and cells, indicates that the suppression of Sproutys
must enhance neovascularization.
In conclusion, Sproutys are physiologically important regulators
of angiogenesis in vivo and may be useful as new therapeutic targets
for peripheral ischemic diseases.
Methods
Mice
Sprouty2 KO mice and Sprouty4 KO mice have been described
previously [21,25]. Sprouty2 KO mice and Sprouty4 KO mice were
generated as 129/C57BL/6J mixed background, and then
backcrossed into C57BL/6J at least five times. Gender-matched,
WT littermates were used as controls. All experiments using these
mice were approved by and performed according to the guidelines
of the Animal Ethics Committee of Kyushu University, Fukuoka,
Japan.
Cell culture
Primary mouse embryonic fibroblasts (MEFs) were prepared, as
previously described [21]. MEFs were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum, penicillin and
streptomycin. To generate MEFs stably expressing VEGFR-2 or
shRNAs, MEFs were infected with the retroviruses produced by
Figure 6. In vivo effects of shRNA targeting Sprouty2 and Sprouty4 in corneal micropocket assay. (A) Corneal neovascularization was
induced by mouse VEGF-A (200 ng) on day 12 after hydron pellets had been implanted into male BALB/c mouse corneas. After implantation, 10 mg
shRNA plasmids per eye were delivered by subconjunctival injection. Representative photos are shown. (B) Quantitative analysis of neovascularization
on day 12. Areas are expressed in mm
2. Bars show the mean6SEM (n=5). *: P,0.05. (C) Sections of corneas implanted with VEGF-A stained by anti-
PECAM-1/CD31Ab on day 12. Scale bars (C): 100 mm.
doi:10.1371/journal.pone.0005467.g006
Figure 5. In vivo effects of shRNA targeting Sprouty2 and Sprouty4. (A) The in vivo effects of shRNA plasmids targeting Sproutys in the hind
limb model were evaluated by RT-PCR analysis. (B, C) Real-time PCR analysis of Sprouty2 (B) or Sprouty4 (C) mRNA expression in MEFs stably infected
with control retroviruses and retroviruses expressing either Sprouty2 shRNA (B) or Sprouty4 shRNA (C). (D, E) Western blot analysis of protein extracts
from MEFs stably infected with control retroviruses and retroviruses expressing either Sprouty2 shRNA (D) or Sprouty4 shRNA (E). The relative
intensities of Sprouty2 and Sprouty4 bands normalized by STAT5 expression levels are shown above. (F) Effect of both Sprouty2 and Sprouty4
knockdown on ERK and Akt activities. MEFs stably expressing VEGFR-2 were infected with control retroviruses and retroviruses expressing Sprouty2/
Sprouty4 shRNA, and stimulated with 100 ng/mL VEGF-A. Cell extracts were immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0005467.g005
Sproutys Inhibit Angiogenesis
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shRNA plasmids, and then the infected cells were selected with
1 mg/ml puromycin (Invivogen, San Diego, CA, USA), as
previously described [18,35].
Antibodies and reagents
Antibodies used in this experiment were as follows: anti-
phospho-ERK1/2 (#9106), anti-phospho-Akt (#4058), and anti-
Akt (#9272) (Cell Signaling Technology, Danvers, MA, USA);
anti-Sprouty4 (H-100), anti-VEGFR-2 (A-3) and anti-ERK2 (C-
14) (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-
Sprouty2 (ab50317) (Abcam, Cambridge, MA, USA); and anti-
vWF (DAKO, Glostrup, Denmark); Mouse VEGF-A was
purchased from R&D Systems (Minneapolis, MN, USA). Human
VEGF-A was purchased from PeproTech (London, UK).
RT-PCR and real-time PCR analysis
The cells or tissues were lysed in RNAiso (TAKARA BIO,
Shiga, Japan) for RNA preparation. Total RNA was isolated
through fluorescence activated cell sorting (FACS), which sorted
about 5.0610
4 BECs and LECs at embryonic day 14.5, as
previously reported [18]. Good separation of BECs and LECs was
confirmed by BEC markers (Nrp1, CD44) and LEC markers
(LYVE-1, Prox1). Total RNA was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA), and the product was used
Figure 7. Increased ischemia-induced angiogenesis by in vivo shRNA targeting Sprouty2 and Sprouty4. (A) Representative laser Doppler
images for each group are depicted. Arrowheads indicate ischemic limbs. The interval of low perfusion is displayed as dark blue; the highest
perfusion interval is displayed as red. (B) Recovery of limb perfusion in C57BL/6J mice (8 weeks old) injected with the control shRNA (n=10) or
Sprouty2/Sprouty4 shRNA vectors (n=12) after hind limb ischemia as assessed by laser Doppler blood flow analysis on day 14. Data shown are
means6SD. *: P,0.05. (C) Blood vessels (green) in the non-ischemic or ischemic adductor muscle injected with the control shRNA or Sprouty2/
Sprouty4 shRNA vectors stained with anti-PECAM-1/CD31Ab. Nuclei were stained with Hoechst 33342 dye (blue). The CD31-positive vessel area was
quantified. Data shown are means6SEM. *: P,0.05. Scale bars (C): 100 mm.
doi:10.1371/journal.pone.0005467.g007
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agarose gel stained with ethidium bromide. The expression level of
GAPDH was evaluated as an internal control. The primer
sequences for RT-PCR were as follows: Sprouty2-F, 59- TTTT-
AATCCACCGATTGCTTGG-39; Sprouty2-R, 59-GCTGCACT-
CGGATTATTCCATC-39; Sprouty4-F, 59-CAGCTCCTCAAA-
GACCCCTAGAAGC-39; Sprouty4-R, 59-GTGCTGCTACTGC-
TGCTTACAGAGC-39; GAPDH-F, 59-ACCACAGTCCATGC-
CATCAC-39 and GAPDH-R 59-TCCACCACCCTGTTGC-
TGTA-39. The primer sequences for BEC and LEC markers
were described elsewhere [36]. Real-time PCR was performed on
cDNA samples using an ABI 7000 Sequence Detection System
(Applied Biosystems) with the SYBR Green system (Applied
Biosystems). The relative quantitation value is expressed as 2
2Ct,
where Ct is the difference between the mean Ct value of triplicates
of the sample and of the endogenous GAPDH control. The primer
sequences for real-time PCR were as follows: Sprouty2-F, 59-
ATAATCCGAGTGCAGCCTAAATC-39; Sprouty2-R, 59-CGC-
AGTCCTCACACCTGTAG-39; Sprouty4-F, 59-CGACCAGAG-
GCTCCTAGATCA-39; Sprouty4-R, 59-CAGCGGCTTACAGT-
GAACCA-39; GAPDH-F, 59-TGTGTCCGTCGTGGATCTGA-
39 and GAPDH-R 59-CCTGCTTCACCACCTTCTTGA-39.
Western blot analysis
Western blot analysis was performed as described previously
[18]. MEFs were lysed in lysis buffer (50 mM Tris-HCl, pH 7.6,
150 mM NaCl, 1% Nonidet P-40, 1 mM sodium vanadate)
supplemented with protease inhibitors (Nacalai tesque, Kyoto,
Japan). About 20 mg of proteins were separated by SDS-PAGE
and transferred to Immobilon-P nylon membranes (Millipore,
Bedford, MA, USA).
Immunohistochemistry
Whole-mount immunohistochemistry of adult ears or immuno-
histochemistry of adult skin was performed with 1:200 diluted anti-
PECAM-1/CD31 (MEC13.3, BD Pharmingen, Franklin Lakes,
NJ, USA) or anti-LYVE-1 antibody (Acris Antibodies, Hidden-
hausen, Germany) essentially as described previously [18].
Retinal angiography
Flat-mounted retinas were evaluated using fluorescein–dextran
angiography as described elsewhere [22]. The mice were deeply
anesthetized and a 0.03 ml/g body weight 50 mg/mL solution of
2610
6 molecular weight FITC–dextran (Sigma, St Louis, MO,
USA) was perfused through the left ventricle. The eyes were
enucleated and fixed in 4% paraformaldehyde for at least 3 h. The
corneas and lenses were then removed, and the peripheral retinas
were dissected and flat-mounted on microscope slides for
examination under a fluorescence microscope.
Vessel quantitative analysis
The vascular area in the ear, skin or muscle was quantified as a
PECAM-1/CD31-positive area from ten 610 micrographs, using
Image J software (http://rsb.info.nih.gov), as described elsewhere
[37]. LYVE-1-positive vessels in the skin were quantified in a
similar manner.
RNAi-mediated knockdown
The mammalian expression vector pSUPER.retro.puro (Oli-
goengine, Seattle, WA, USA) was used for expression of shRNA
targeting murine Sprouty2. The sequence of the Sprouty2 shRNA is
59-GCCGGGTTGTCGTTGTAAA-39 and corresponds to nu-
cleotides 1150–1168 of mSprouty2. Murine Sprouty4 shRNA (29-
mer) and control plasmids were purchased from Origene (Rock-
ville, MD, USA) and used according to the manufacturer’s
protocols. The specificity of Sprouty2 and Sprouty4 knockdown was
confirmed by real-time PCR or immunoblotting of whole-cell
lysates of MEFs with anti-Sprouty2 and anti-Sprouty4 antibodies,
respectively. The relative intensities of Sprouty2 or Sprouty4 band
were normalized by STAT5 expression using Image J software, as
previously described [9,35].
In vivo models of ischemia
A hind limb ischemia model was performed as previously
described [23,38]. Male WT and Sprouty4 KO mice (8–10 weeks
old) and male C57BL/6J mice (8 weeks old) were used for a
hind limb ischemia model. The proximal portion of the right
femoral artery including the superficial and the deep branch and
the distal portion of the saphenous artery were occluded with an
electrical coagulator. After 2 weeks, we determined the ischemic
(right)/nonischemic (left) limb blood flow ratio by using a laser
Doppler blood flow imager (Laser Doppler Perfusion Imager
System, moorLDI-Mark 2; Moor Instruments, Wilmington, DE,
USA). Before initiating scanning, mice were placed on a heating
pad at 37uC to minimize variations in their body temperatures.
Calculated perfusion is expressed as the ratio of ischemic to
nonischemic hind limb perfusion. At 2 wk after femoral
resection, adductor muscles from the ischemic and control limbs
were embedded in OCT compound. Eight-micron sections were
stained with anti-PECAM-1/CD31 antibody (BD Pharmingen)
and anti-rat Ig secondary antibody. For in vivo shRNA targeting
Sprouty2 and Sprouty4, a hind limb ischemia model was
performed. Immediately after ischemia was induced, either a
total of 40 mg Sproutys shRNA vectors (20 mg Sprouty2 shRNA
vector and 20 mg Sprouty4 shRNA vector) or a quantity of
control shRNA vectors was injected into five different sites in the
adductor muscle of each anesthetized mouse [32]. A model of
soft tissue ischemia similar to one described elsewhere [24,39]
was developed. The model consisted of lateral skin incisions
(2.5 cm in length and 1.25 cm apart) created on the dorsal
surface of mice, penetrating the skin, dermis, and underlying
adipose tissue. The overlying skin was undermined, and a 0.13-
mm-thick silicone sheet was inserted to separate the skin from
the underlying tissue bed. The skin was then reapproximated
with 6-0 nylon sutures.
Corneal micropocket assay
The mouse corneal micropocket assay and quantification of
neovascularization were performed as described elsewhere [40],
using male BALB/c mice (6–10 weeks old). For local delivery,
shRNA plasmids (total 10 mg/10 ml per eye) were diluted in
phosphate-buffered saline (PBS) and delivered subconjunctivally.
The subconjunctival injections were given after hydron pellet
implantation.
Statistical analysis
Data are expressed as mean6SD or mean6SEM. Statistical
significance was tested with an unpaired two-tailed Student’s t-test
or analysis of variance (ANOVA). The differences were considered
to be significant if P,0.05.
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